The US Food and Drug Administration (FDA) has granted Fast Tack Designation for an immune medicine targeting triple-negative breast cancer.  RPTR-1-201 is a novel T cell receptor (TCR) bispecific immune medicine, developed by biotechnology company Repertoire Immune Medicines, that is currently in a Phase I/II trial for the treatment of multiple advanced solid tumours.  The treatment […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!